THE CHANDLER PROJECT JOINS GLOBAL GENES RARE-X PROGRAM
via Murdoch Children’s Research Institute A drug that boosts bone growth in children with achondroplasia may also reduce their chances of sudden infant death syndrome (SIDS), sleep apnoea and needing…
SOURCE: AGENDA.GE Agenda.ge, 14 Nov 2023 – 15:18, Tbilisi,Georgia Vosoritide, a medication used for the treatment of achondroplasia among children patients, is now available in Georgia, the country’s Ministry of…
Obtained from UBMD Physicians’ Group website. This article was written by Dirk Hoffman and published on November 9, 2023. Teresa Quattrin, MD, UB Distinguished Professor of pediatrics, is a co-author on…
The following press release was obtained from BioMarin.com. To learn more about BioMarin, VOXZOGO®, vosorotide, and their other pipelines and research for achondroplasia and other skeletal dysplasias, click here. Expanded…
The Murdoch Children’s Research Institute has welcomed the news that children born with the most common form of dwarfism, achondroplasia, will have access to a new life-changing treatment on the Pharmaceutical Benefits Scheme (PBS).
Svein O. Fredwall, Jennifer Linge, Olga de Vries, Olof Dahlqvist Leinhard, Heidi Beate Eggesbø, Harald Weedon-Fekjær, Mikael Petersson, Per Widholm, Grethe Månum & Ravi Savarirayan Orphanet Journal of Rare Diseases volume 18, Article number: 35 (2023) ABSTRACT BACKGROUNDSymptomatic spinal stenosis is a prevalent complication in…
